

DAFTAR PUSTAKA

- Cattley RC, Cullen JM. Liver and Gall Bladder. Third Edit. Fundamentals of Toxicologic Pathology; 2018
- Lu L. Guidelines for the Management of Cholestatic Liver Diseases (2021). *J Clin Transl Hepatol* 2022;10(4):757–69. Available from: <https://www.doi.org/10.14218/JCTH.2022.00147>
- Nietsche TR, Dotta G, Barcaui CB, Ferraz MLCG. Cholestatic pruritus: a knowledge update. *An Bras Dermatol*. 2022;97(3):332-337. doi:10.1016/j.abd.2021.06.007
- Tidwell J, Wu GY. Heritable Chronic Cholestatic Liver Diseases: A Review. *J Clin Transl Hepatol*. 2024;12(8):726-738. doi:10.14218/JCTH.2024.00119
- Rodrigo M, Dong X, Chien D, Karnsakul W. Cholestatic Pruritus in 54 Children: Conventional Therapies and Beyond. *Biology (Basel)* 2023;12(5):1–1
- Cattley RC, Cullen JM. Liver and Gall Bladder. Third Edit. Fundamentals of Toxicologic Pathology; 2018
- Paul C, Maumus-Robert S, Mazereeuw-Hautier J, Guyen CN, Saudez X, Schmitt AM. (2011). Prevalence and Risk Factors for Xerosis in the Elderly: A Cross-Sectional Epidemiological Study in Primary Care Dermatology [Internet]. 223(3):260–5. [Diakses pada 27 Oktober 2022]. Diunduh dari: <https://www.ncbi.nlm.nih.gov/pubmed/22104182>.
- Ye L, Wang Z, Li Z, Lv C, Man MQ. 2019. Validation of GPSkin Barrier ® for assessing epidermal permeability barrier function and stratum corneum hydration in humans. *Ski Res Technol*.
- Berardesca, E. (2012). *EEMCO guidance for the assessment of stratum corneum hydration: Electrical methods*. *Skin Research and Technology*, 18(1), 1–6. <https://doi.org/10.1111/j.1600-0846.2011.00554.x>
- Blichmann, C. W., & Serup, J. (1988). Assessment of skin moisture. *Measurement of electrical conductance*. *Acta Dermato-Venereologica*, 68(4), 284–290.

- Darlenski, R., Sassning, S., Tsankov, N., & Fluhr, J. W. (2009). Non-invasive in vivo methods for investigation of the skin barrier physical properties. *European Journal of Pharmaceutics and Biopharmaceutics*, 72(2), 295–303. <https://doi.org/10.1016/j.ejpb.2008.11.013>
- Lodén, M., Hagforsen, E., & Lindberg, M. (1995). The presence of body hair influences the measurement of skin hydration with the Corneometer. *Acta Dermato-Venereologica*, 75(6), 449–450.
- Załęcki, P., Rogowska, K., Wąs, P., Łuczak, K., Wysocka, M., & Nowicka, D. (2024). Impact of lifestyle on differences in skin hydration of selected body areas in young women. *Cosmetics*, 11(1), 13. <https://doi.org/10.3390/cosmetics11010013>
- Van Wettère AJ. Histologic Patterns of Hepatotoxic Injury [Internet]. Third Edit. Elsevier; 2018. Available from: <http://dx.doi.org/10.1016/B978-0-12-801238-3.10921-3>
- Tajiri K, Shimizu Y. Recent advances in the management of pruritus in chronic liver diseases. *World J Gastroenterol*. 2017;23(19):3418–26. <https://doi.org/10.3748/wjg.v23.i19.3418>. PMID: 28596678; PMCID: PMC5442078
- Kamath BM, Baker A, Houwen R, Todorova L, Kerkar N. Systematic review: the epidemiology, natural history, and burden of alagille syndrome. *J Pediatr Gastroenterol Nutr*. 2018;67(2):148–56. <https://doi.org/10.1097/MPG.0000000000001958>. PMID: 29543694; PMCID: PMC6110620
- Younossi ZM, Bernstein D, Shifman ML, Kwo P, Kim WR, Kowdley KV, Jacobson IM. Diagnosis and management of primary biliary cholangitis. *Am J Gastroenterol*. 2019;114(1):48–63. <https://doi.org/10.1038/s41395-018-0390-3>
- Van Munster KN, Dijkgraaf MGW, Oude Elferink RPJ, Beuers U, Ponsioen CY. Symptom patterns in the daily life of PSC patients. *Liver Int*. 2022;42(7):1562–70. <https://doi.org/10.1111/liv.15271>. Epub 2022 Apr 18. PMID: 35396817; PMCID: PMC9325051
- Mighiu C, O'Hara S, Ferri Grazzi E, Murray KF, Schattenberg JM, Ventura E, Karakaidos M, Taylor A, Brrang H, Dhawan A, Willemse J, Finnegan A. Impact of progressive familial intrahepatic cholestasis on caregivers: caregiver-reported outcomes from the multinational PICTURE study. *Orphanet J Rare Dis*. 2022;17(1):32.

<https://doi.org/10.1186/s13023-022-02177-0>. PMID: 35109890; PMCID: PMC8809495

Mayo MJ, Carey E, Smith HT, Mospan AR, McLaughlin M, Thompson A, Morris HL, Sandefur R, Kim WR, Bowlus C, Investigators TARGET-PBC, Levy C. Impact of pruritus on quality of life and current treatment patterns in patients with primary biliary cholangitis. *Dig Dis Sci*. 2023;68(3):995–1005. <https://doi.org/10.1007/s10620-022-07581-x>. Epub 2022 Jun 15

Smith HT, de Souza AR, Thompson AH, McLaughlin MM, Dever JJ, Myers JA, Chen JV. Cholestatic pruritus treatments in primary biliary cholangitis and primary sclerosing cholangitis: a systematic literature review. *Dig Dis Sci*. 2023;68(6):2710–30. <https://doi.org/10.1007/s10620-023-07862-z>. Epub 2023 Mar 18. PMID: 36933112; PMCID: PMC10024020

Vander Does A, Levy C, Yosipovitch G. Cholestatic itch: our current understanding of pathophysiology and treatments. *Am J Clin Dermatol*. 2022;23(5):647–59. <https://doi.org/10.1007/s40257-022-00710-2>. Epub 2022 Jul 28

Varadi DP. Pruritus induced by crude bile and purified bile acids. Experimental production of pruritus in human skin. *Arch Dermatol*. 1974;109(5):678–81.

Crosignani A, Del Puppo M, Longo M, De Fabiani E, Caruso D, Zuin M, Podda M, Javitt NB, Kienle MG. Changes in classic and alternative pathways of bile acid synthesis in chronic liver disease. *Clin Chim Acta*. 2007;382:82–8.

Staels B, Fonseca VA. Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration. *Diabetes 133 Current Hepatology Reports (2024)* 23:123–136 Care. 2009;32(Suppl 2(Suppl 2)):S237–45. <https://doi.org/10.2337/dc09-S355>. PMID: 19875558; PMCID: PMC2811459

Stiehl A. Bile acids and bile acid sulfates in the skin of patients with cholestasis and pruritus. *Z Gastroenterol*. 1974;12(2):121–4.

Alemi F, Kwon E, Poole DP, Lieu T, Lyo V, Cattaruzza F, et al. The TGR5 receptor mediates bile acid-induced itch and analgesia. *J Clin Invest*. 2013;123(4):1513–30. <https://doi.org/10.1172/JCI64551>

- Patel SP, Vasavda C, Ho B, Meixiong J, Dong X, Kwatra SG. Cholestatic pruritus: emerging mechanisms and therapeutics. *J Am Acad Dermatol*. 2019;81(6):1371–8. <https://doi.org/10.1016/j.jaad.2019.04.035>. Epub 2019 Apr 19. PMID: 31009666; PMCID: PMC7825249
- Xu J, Wang Y, Khoshdeli M, Peach M, Chuang JC, Lin J, Tsai WW, Mahadevan S, Minto W, Diehl L, Gupta R, Trauner M, Patel K, Nouredin M, Kowdley KV, Gulamhusein A, Bowlus CL, Huss RS, Myers RP, et al. IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH. *Hepatology*. 2023;77(1):20–32. <https://doi.org/10.1002/hep.32599>. Epub 2022 Jul 17. PMID: 35686937; PMCID: PMC9970017
- Kabashima K, Irie H. Interleukin-31 as a clinical target for pruritus treatment. *Front Med (Lausanne)*. 2021;12(8):638325. <https://doi.org/10.3389/fmed.2021.638325>. PMID: 33644103; PMCID: PMC7906974
- Geraldo LHM, Spohr TCLDS, Amaral RFD, et al. Role of lysophosphatidic acid and its receptors in health and disease: novel therapeutic strategies. *Signal Transduct Target Ther*. 2021;6:45. <https://doi.org/10.1038/s41392-020-00367-5>.
- Kremer AE, Martens JJ, Kulik W, Ruëf F, Kuiper EM, van Buuren HR, van Erpecum KJ, Kondrackiene J, Prieto J, Rust C, Geenes VL, Williamson C, Moolenaar WH, Beuers U, Oude Elferink RP. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. *Gastroenterology*. 2010;139(3):1008–18, 1018.e1.
- Kittaka H, Uchida K, Fukuta N, Tominaga M. Lysophosphatidic acid-induced itch is mediated by signalling of LPA5 receptor, phospholipase D and TRPA1/TRPV1. *J Physiol*. 2017;595(8):2681–98. <https://doi.org/10.1113/JP273961>. Epub 2017 Mar 22. PMID: 28176353; PMCID: PMC5390871
- Omari SA, Adams MJ, Geraghty DP. TRPV1 Channels in immune cells and hematological malignancies. *Adv Pharmacol*. 2017;79:173–98. <https://doi.org/10.1016/bs.apha.2017.01.002>. Epub 2017 Mar 21
- Guimaraes MZP, Jordt SE. TRPA1 : A sensory channel of many talents. In: Liedtke WB, Heller S, editors. *TRP ion channel function in sensory*

transduction and cellular signaling cascades. Boca Raton (FL): CRC Press/Taylor & Francis; 2007. Chapter 11. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK5237/>.

Bujak JK, Kosmala D, Szopa IM, Majchrzak K, Bednarczyk P. Inflammation, cancer and immunity-implication of TRPV1 channel. *Front Oncol*. 2019;16(9):1087. <https://doi.org/10.3389/fonc.2019.01087>. s

YY, Peng BW. Modulation of neuroinflammation: role and therapeutic potential of TRPV1 in the neuroimmune axis. *Brain Behav Immun*. 2017;64:354–66. <https://doi.org/10.1016/j.bbi.2017.03.007>. Epub 2017 Mar 22

Kremer AE, van Dijk R, Leckie P, Schaap FG, Kuiper EM, Mettang T, Reiners KS, et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. *Hepatology*. 2012;56(4):1391–400.

Leckie P, Tritto G, Mookerjee R, Davies N, Jones D, Jalan R. ‘Out-patient’ albumin dialysis for cholestatic patients with intractable pruritus. *Aliment Pharmacol Ther*. 2012;35(6):696–704. <https://doi.org/10.1111/j.1365-2036.2012.04994.x>. Epub 2012 Jan 20

Langedijk JAGM, Beuers UH, Oude Elferink RPJ. Cholestasis-associated pruritus and its pruritogens. *Front Med (Lausanne)*. 2021;9(8):639674. <https://doi.org/10.3389/fmed.2021.639674>. PMID: 33791327; PMCID: PMC8006388

Bergasa NV. The itch of liver disease. *Semin Cutan Med Surg*. 2011;30:93–8.

Zagon IS, McLaughlin PJ. Endogenous opioids in the etiology and treatment of multiple sclerosis. In: Zagon IS, McLaughlin PJ, editors. *Multiple sclerosis: perspectives in treatment and pathogenesis*. Brisbane (AU): Codon Publications; 2017. Chapter 8. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK470156/>. <https://doi.org/10.15586/codon.multiplesclerosis.2017.ch8>. Accessed 27 Nov

Snyder LM, Kuzirian MS, Ross SE. An unexpected role for TRPV4 in serotonin-mediated itch. *J Invest Dermatol*. 2016;136(1):7–9.

<https://doi.org/10.1016/j.jid.2015.11.010>. PMID: 26763416; PMCID: PMC4758363

- Browning J, Combes B, Mayo MJ. Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis. *Am J Gastroenterol*. 2003;98(12):2736–41.
- Schwörer H, Ramadori G. Improvement of cholestatic pruritus by ondansetron. *Lancet*. 1993;341(8855):1277. [https://doi.org/10.1016/0140-6736\(93\)91178-o](https://doi.org/10.1016/0140-6736(93)91178-o).
- Yu H, Zhao T, Liu S, Wu Q, Johnson O, Wu Z, Zhuang Z, Shi Y, Peng L, He R, Yang Y, Sun J, Wang X, Xu H, Zeng Z, Zou P, Lei X, Luo W, Li Y. MRGPRX4 is a bile acid receptor for human cholestatic itch. *eLife*. 2019;8:e48431. <https://doi.org/10.7554/eLife.48431>.
- Meixiong J, Vasavda C, Green D, Zheng Q, Qi L, Kwatra SG, Hamilton JP, Snyder SH, Dong X. Identification of a bilirubin receptor that may mediate a component of cholestatic itch. *eLife*. 2019;8:e44116. <https://doi.org/10.7554>

LAMPIRAN

Lampiran 1. Surat Rekomendasi Etik



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Aguslaim Bukhari., MMed, PhD, SpCK, TELP. 081241850858, 0411 5780103, Fax : 0411-581431



REKOMENDASI PERSETUJUAN ETIK

Nomor : 72/UN4.6.4.5.31/ PP36/ 2025

Tanggal: 3 Februari 2025

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH25010052	No Sponsor	
Peneliti Utama	dr. Budi Rahmawati	Sponsor	
Judul Peneliti	Hubungan Kadar Gamma Glutamyl Transferase, Alkali Fosfatase, Bilirubin, dan Kolesterol Terhadap Tingkat Kekeringan Kulit dan Derajat Pruritus Pasien Kolestasis Kronis		
No Versi Protokol	2	Tanggal Versi	31 Januari 2025
No Versi PSP	2	Tanggal Versi	31 Januari 2025
Tempat Penelitian	RSUP dr. Wahidin Sudirohusodo Makassar		
Jenis Review	☐ Exempted ☒ Expedited ☐ Fullboard Tanggal	Masa Berlaku 3 Februari 2025 sampai 3 Februari 2026	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Prof. dr. Muh Nasrum Massi, PhD, SpMK, Subsp. Bakt(K)	Tanda tangan 	
Sekretaris KEP Universitas Hasanuddin	dr. Firdaus Hamid, PhD, SpMK(K)	Tanda tangan 	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 jam dan dilengkapi dalam 7 hari dan Laport SUSAR dalam 72 jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran 2 : Pelaksanaan penelitian

